Contact this trialFirst, we need to learn more about you.
Activator
AG-348 for Thalassemia
Recruiting1 awardPhase 2
Oakland, California
This trial is testing a new drug, AG-348, for adults with non-transfusion-dependent thalassemia, a genetic blood disorder. The trial includes a core period of 24 weeks followed by an extension period of up to 10 years for eligible participants.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service